Schizophrenia Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Schizophrenia Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 26
00:29 2023
Schizophrenia Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Schizophrenia Pipeline Insights
DelveInsight’s, “Schizophrenia – Pipeline Insight, 2023,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Schizophrenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

United States, Nevada, Las Vegas, DelveInsight’s Schizophrenia Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Schizophrenia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Schizophrenia pipeline domain.

Key Takeaways from the Schizophrenia Pipeline Report

  • Over 70+ Schizophrenia pipeline therapies are in various stages of development, and their anticipated acceptance in the Schizophrenia market would significantly increase market revenue. 
  • Leading Schizophrenia companies developing novel drug candidates to improve the Schizophrenia treatment landscape include Otsuka Pharmaceutical, Takeda, Cyclerion Therapeutics, Avanir Pharmaceuticals, and others.
  • Promising Schizophrenia pipeline therapies in various stages of development include Ulotaront, Luvadaxistat, CY6463, AVP 786, and others.

Schizophrenia Overview

Schizophrenia causes psychosis and is associated with considerable disability and may affect all areas of life including personal, family, social, educational, and occupational functioning. It is thought that an interaction between genes and a range of environmental factors may cause schizophrenia. Psychosocial factors may also affect the onset and course of schizophrenia. Heavy use of cannabis is associated with an elevated risk of the disorder. Schizophrenia is characterized by significant impairments in the way reality is perceived and changes in behaviour related to: Persistent delusions, persistent hallucinations, experiences of influence, control or passivity, disorganized thinking, highly disorganized behavior, “negative symptoms” such as very limited speech, extreme agitation or slowing of movements etc. diagnosis of schizophrenia is reached through an assessment of patient-specific signs and symptoms like delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms. Treatment is usually lifelong and often involves a combination of medications, psychotherapy and coordinated speciality care services.

Schizophrenia Pipeline Analysis: Drug Profile

Ulotaront: Otsuka Pharmaceutical

Ulotaront (SEP-363856), one of the first of a new class of CNS-active compounds, is an agonist at trace amine-associated receptor 1 (TAAR1) as well as serotonin 5-HT1A receptors. TAAR1 is a G-protein-coupled receptor expressed in cortical, limbic, and midbrain monoaminergic regions that modulate dopaminergic, serotonergic, and glutamatergic activity. In contrast to first- and second-generation antipsychotics, the efficacy of ulotaront is not mediated by blockade of D2 or 5-HT2A receptors. Ulotaront has demonstrated positive effects in rodent models assessing endophenotypes of schizophrenia, including phencyclidine (PCP)-induced hyperactivity, prepulse inhibition, and PCP-induced deficits in social interaction and cognition. An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia. It’s currently in phase III stage of development.

Discover more about the emerging Schizophrenia drugs @ Schizophrenia Treatment Drugs

Schizophrenia Key Companies

  • Otsuka Pharmaceutical
  • Takeda
  • Cyclerion Therapeutics
  • Avanir Pharmaceuticals

Schizophrenia Pipeline Therapies

  • Ulotaront
  • Luvadaxistat
  • CY6463
  • AVP 786

Schizophrenia Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Schizophrenia Pipeline Report 

  • Coverage: Global 
  • Key Schizophrenia Companies: Otsuka Pharmaceutical, Takeda, Cyclerion Therapeutics, Avanir Pharmaceuticals, and others
  • Key Schizophrenia Pipeline Therapies: Ulotaront, Luvadaxistat, CY6463, AVP 786, and others

Find out more about the Schizophrenia treatment options in development @ Schizophrenia Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the Schizophrenia pipeline domain.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States